Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 17:2021:9976067.
doi: 10.1155/2021/9976067. eCollection 2021.

Functional Status of Pancreatic α and β Cells in Type 2 Diabetes Mellitus Patients with Different Plasma Triglyceride Levels: A Retrospective Analysis

Affiliations

Functional Status of Pancreatic α and β Cells in Type 2 Diabetes Mellitus Patients with Different Plasma Triglyceride Levels: A Retrospective Analysis

Hang Guo et al. Int J Endocrinol. .

Abstract

Objective: To investigate the functional status of pancreatic α and β cells in Type 2 diabetes mellitus (T2DM) patients with different plasma triglyceride (TG) levels. TG levels can be prognostic markers for T2DM.

Methods: A total of 328 patients with T2DM were divided into three groups according to different TG levels: the TGL group: TG < 1.7 mmol/L; TGM group: 1.7 mmol/L ≤ TG < 2.3 mmol/L; and TGH group: TG ≥ 2.3 mmol/L. An oral glucose tolerance test (OGTT), insulin release test, and glucagon release test were performed in each patient. The changes of glucagon, glucagon/insulin ratio, early insulin secretion index (ΔI 30G 30), and area under the insulin curve (AUCI) were compared among each group. Also, the correlations between glucagon and pancreatic β-cell function, glycosylated hemoglobin (HbA1c), and other indices were analyzed.

Results: With the increase of TG, the fasting and postprandial glucagon levels, the glucagon/insulin ratio, and the area under the glucagon curve (AUCG) presented an increasing trend. The homeostasis model assessment of insulin resistance (HOMA-IR) of the TGH group was significantly increased compared to the TGL and TGM groups. In addition to the increase in TG levels, the insulin sensitivity index (ISI), homeostasis model assessment for β-cell function index (HOMA-β), ΔI 30G 30, and AUCI displayed a reducing trend. Glucagon was negatively correlated with ΔI 30G 30, high-density lipoprotein (HDL), HOMA-β, body mass index (BMI), ISI, and AUCI (P < 0.05) and positively correlated with fasting blood glucose (FPG), AUCG, HOMA-IR, HbA1c, duration, TG, low-density lipoprotein (LDL), and total cholesterol (TC) (P < 0.05).

Conclusion: Hypertriglyceridemia aggravated the dysfunction of pancreatic α and β cells. A reasonable control of the TG level makes it easier for blood glucose to reach the standard.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Glucagon and glucagon/insulin before and after OGTT among patients with different HbA1c. TGL: TG < 1.7 mmol/L; TGM: TGM 1.7 ≤ TG < 2.3 mmol/L; and TGH: TG ≥ 2.3 mmol/L. P < 0.05 versus TCL; #P < 0.05 versus TCM.
Figure 2
Figure 2
Islet β-cell function and AUCG among patients with different HbA1c levels. TGL: TG < 1.7 mmol/L; TGM: TGM 1.7 ≤ TG < 2.3 mmol/L; and TGH: TG ≥ 2.3 mmol/L. AUCG: area under the curve of glucose; ΔI30G30: ratio of insulin increment and glucose increment 30 min after glucose load; AUCI: area under the curve of insulin; HOMA-β: homeostasis model assessment of β-cell function; HOMA-IR: homeostasis model assessment of insulin resistance index; and ISI: insulin sensitivity index. P < 0.05 versus TCL; #P < 0.05 versus TCM.

Similar articles

Cited by

References

    1. Chatterjee S., Khunti K., Davies M. J. Type 2 diabetes. Lancet. 2010;389(10085):2239–2251. - PubMed
    1. Forouhi N. G., Wareham N. J. Epidemiology of diabetes. Medicine. 2014;42(12):698–702. doi: 10.1016/j.mpmed.2014.09.007. - DOI - PMC - PubMed
    1. Hu C., Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67(1):3–11. doi: 10.2337/dbi17-0013. - DOI - PubMed
    1. Zimmet P., Alberti K. G., Magliano D. J., Bennett P. H. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nature Reviews Endocrinology. 2016;12(10):616–622. doi: 10.1038/nrendo.2016.105. - DOI - PubMed
    1. Kasuga M. Insulin resistance and pancreatic cell failure. Journal of Clinical Investigation. 2006;116(7):1756–1760. doi: 10.1172/jci29189. - DOI - PMC - PubMed

LinkOut - more resources